Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Neopharm Co., Ltd. (092730:KRX), powered by AI.
Neopharm Co., Ltd. is currently trading at ₩17,600. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Neopharm Co., Ltd. on Alpha Lenz.
Neopharm Co., Ltd.'s P/E ratio is 10.1.
“Neopharm Co., Ltd. trades at a P/E of 10.1 (undervalued) with solid ROE of 14.9%. 3Y revenue CAGR of 15.8% highlights clear growth momentum.”
Ask for details →Neopharm Co., Ltd. is a prominent player in the biotechnology sector, specializing in the development and production of innovative skincare and dermatology products. The company's primary focus is on advancing skin barrier technologies that cater to a wide range of dermatological needs. Neopharm leverages its cutting-edge research and development capabilities to create a diverse portfolio of products aimed at improving skin health and treating various dermatological conditions. Key industries impacted by Neopharm's offerings include healthcare, pharmaceuticals, and cosmetics, reflecting its unique positioning at the intersection of therapeutic and cosmetic skincare solutions. Neopharm Co., Ltd. is recognized for its commitment to quality and innovation, continuously driving advancements in skin science. Within the financial markets, Neopharm's contributions to the skincare and biotech fields underscore its relevance, appealing to investors interested in companies that blend scientific research with practical health applications. Established in an era of growing awareness around skincare, Neopharm Co., Ltd. plays a vital role in meeting the increasing global demand for effective and scientifically-backed skincare solutions.
“Neopharm Co., Ltd. trades at a P/E of 10.1 (undervalued) with solid ROE of 14.9%. 3Y revenue CAGR of 15.8% highlights clear growth momentum.”
Ask for details →Neopharm Co., Ltd. (ticker: 092730) is a company listed on KRX in the Common Stock sector (Common Stock). Market cap is $282.1B.
The current price is ₩17,600 with a P/E ratio of 10.14x and P/B of 1.44x.
ROE is 14.95% and operating margin is 21.77%. Annual revenue is $132.2B.